Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial

Mayer K, Hein-Rothweiler R, Schüpke S, et al. for the ISAR-Plaster investigators. Get the PDF – Get the Supplemental Online Content